Cargando…

T-ALL Cells as Tool Cells for CAR T Therapy

T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic malignancy derived from T cells. Numerous CAR T therapies have been successfully applied to treat hematologic malignancies in the clinic. Nevertheless, there remain several challenges to the extensive application of CAR T cell therapy in T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Anqi, Zhao, Yuan, Zhu, Haichuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142624/ https://www.ncbi.nlm.nih.gov/pubmed/37112766 http://dx.doi.org/10.3390/vaccines11040854

Ejemplares similares

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
por: Ren, Anqi, et al.
Publicado: (2023)

CAR‐T therapy as a consolidation in remission B‐ALL patients with poor prognosis
por: Yin, Zhichao, et al.
Publicado: (2022)

In vivo generated human CAR T cells eradicate tumor cells
por: Agarwal, Shiwani, et al.
Publicado: (2019)

Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL
por: Chen, Long, et al.
Publicado: (2023)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting
por: Lohmueller, Jason J., et al.
Publicado: (2017)

Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
por: Schubert, Maria-Luisa, et al.
Publicado: (2020)

Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro
por: Da Rocha, Mathieu Neto, et al.
Publicado: (2022)

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021)

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma
por: Messerli, Christian, et al.
Publicado: (2023)

Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
por: Chen, Gregory M., et al.
Publicado: (2023)

Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy
por: Tang, Jack Pengfei, et al.
Publicado: (2022)

Car tire injuries: a review of 35 patients
por: Suliman, M. Taifour, et al.
Publicado: (2008)

Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application
por: Erdoğan, Ebru, et al.
Publicado: (2022)

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

Reactions Related to CAR-T Cell Therapy
por: Miao, Lele, et al.
Publicado: (2021)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
por: Li, Xin, et al.
Publicado: (2021)

Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy
por: Coorens, Tim H. H., et al.
Publicado: (2023)

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells
por: Grain, Audrey, et al.
Publicado: (2023)

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
por: Grote, Stefan, et al.
Publicado: (2020)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy
por: Rudek, Loreen Sophie, et al.
Publicado: (2021)

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy
por: Wu, Jianghua, et al.
Publicado: (2023)

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
por: Forsberg, Matthew H, et al.
Publicado: (2018)

Development of CAR-T cell therapy for B-ALL using a point-of-care approach
por: de Macedo Abdo, Luiza, et al.
Publicado: (2020)

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
por: Garfall, Alfred L., et al.
Publicado: (2023)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Advances in Universal CAR-T Cell Therapy
por: Lin, Haolong, et al.
Publicado: (2021)

Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy
por: Nair, Ranjit, et al.
Publicado: (2020)

Dasatinib for treatment of CAR T-cell therapy-related complications
por: Baur, Katharina, et al.
Publicado: (2022)

Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series
por: Fontanelli, Lorenzo, et al.
Publicado: (2023)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT
por: Zhao, Jie, et al.
Publicado: (2023)

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function
por: Sahillioglu, Ali Can, et al.
Publicado: (2021)

The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
por: Hucks, George, et al.
Publicado: (2019)

Smoke-Free Rules in Homes and Cars Among Smokers and Nonsmokers in Minnesota
por: Parks, Michael J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0p2vg7slu40djho68c001e396d